Alpine Immune Sciences provides a protein‑engineering platform that creates bifunctional and multivalent therapeutics to simultaneously target multiple immune checkpoints. By combining computational design, modular scaffolds, and high‑throughput functional screening, it generates precision immunotherapies with controlled geometry and valency for oncology and autoimmune indications, enabling pharma partners to develop more specific and potent immune‑modulating drugs.
Funding
$150M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current immune‑modulating therapies often rely on single‑target checkpoint inhibitors, which can lead to limited efficacy, resistance development, and off‑target immune activation in both oncology and autoimmune indications.
Solution
Alpine Immune Sciences addresses these gaps with a protein‑engineering platform that designs bifunctional and multivalent therapeutics capable of simultaneously engaging multiple immune checkpoints. By precisely controlling the geometry and valency of binding domains, the platform creates novel mechanisms of action that can either amplify or suppress specific immune pathways as needed. The resulting molecules are engineered for high specificity, reducing collateral immune activation while enhancing therapeutic potency. Preclinical pipelines integrate structural modeling, high‑throughput screening, and functional assays to rapidly iterate candidate designs. This approach enables the generation of precision immunotherapies tailored for cancer immuno‑oncology as well as for autoimmune disease modulation.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing next‑generation immunotherapies for oncology and autoimmune disease programs.
Features
- Modular protein scaffold allowing rapid assembly of bifunctional or multivalent binding domains
- Computational design suite that predicts optimal epitope orientation and affinity for targeted checkpoints
- High‑throughput cell‑based functional screening to assess selective activation or inhibition of immune pathways
- Integrated manufacturability pipeline supporting scalable recombinant expression and purification
- In‑vivo validation models for both tumor immunity and autoimmune disease contexts
- Proprietary linker technologies that fine‑tune spatial proximity and signaling outcomes of engaged receptors